MedTrace Logo

HIV-1 Viral Dynamics in Subjects Initiating Raltegravir Therapy

NCT00709397 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 3

Last updated 2010-08-02

No results posted yet for this study

Summary

This study is designed to determine how quickly HIV-1 is cleared from the blood in treatment-experienced patients beginning a salvage therapy regimen that includes the integrase inhibitor raltegravir. The hypothesis is that HIV-1 is cleared as rapidly in these patients as in treatment-naive patients starting a raltegravir-based regimen.

Conditions

  • HIV-1 Infection

Interventions

OTHER

blood drawing

Subjects will have been prescribed raltegravir (400 mg BID) by their primary physicians. Such subjects will have frequent blood sampling in this study to monitor the virologic response to raltegravir therapy.

Sponsors & Collaborators

Principal Investigators

  • Daniel R Kuritzkes, MD · Brigham and Women's Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00709397 on ClinicalTrials.gov